The Department of Biotechnology has launched a major funding call for research and development targeting next-generation T-cell-based vaccines, biologics, and cellular therapies for infectious diseases, cancer, and autoimmune disorders, according to official program documents. Applications remain open through October 6, 2026, targeting interventions designed to harness T-cell responses for disease prevention and treatment.
Research Scope and Disease Targets
The funding supports both fundamental and translational research addressing major health challenges across three primary clinical areas, according to program specifications. For infectious diseases, eligible research proposals may focus on dengue, Hepatitis B virus (HBV), Cytomegalovirus (CMV), influenza, and tuberculosis.
Cancer research areas supported by the call include HPV-associated cancers, colorectal cancer, breast cancer, lung cancer, ovarian cancer, haematological malignancies, and melanomas. For autoimmune disorders, projects may address lupus, rheumatoid arthritis, multiple sclerosis, celiac disease, type I diabetes, and psoriasis, as outlined by the Department of Biotechnology.
Funding Categories and Financial Limits
Financial support is divided into three project types based on scale and investigator involvement, according to the Department of Biotechnology. Principal Investigator (PI)-driven projects are eligible for up to INR 2.5 crores. Collaborative projects involving at least two PIs can receive up to INR 10 crores. Network projects involving 3–5 PIs or institutes are eligible for up to INR 15 crores.
Pro tip: PIs should coordinate carefully before applying, as each PI may participate in only one proposal under this call.
Projects receive initial support for up to three years. An extension of up to two additional years may be possible based on project progress, according to program guidelines.
Eligible Institutions and Submission Process
The call is open to Indian nationals holding regular positions in DSIR-recognized academic or scientific institutions, according to the official notice. Eligible organizations include central government institutions, state government institutions, private universities, research institutions, and DSIR-recognized NGOs registered on the DARPAN Portal.
Applicants must submit their proposals through the Department of Biotechnology’s e-ProMIS portal by the October 6, 2026 deadline. The programme encompasses foundational research and capacity building, applied research and technology development, and early clinical development, supporting everything from antigen discovery to GMP manufacturing.
Did you know? The initiative supports activities such as antigen discovery, vaccine platforms, and early-phase clinical evaluation.
Frequently Asked Questions
What is the final deadline to submit proposals?
The last date to submit proposals through the e-ProMIS portal is October 6, 2026, according to the Department of Biotechnology.
How much funding can a network project receive?
Network projects involving 3–5 PIs or institutes can receive up to INR 15 crores, according to program documents.
Who is eligible to apply as a lead Principal Investigator?
Indian nationals holding regular positions in DSIR-recognized academic or scientific institutions can apply, as specified by the funding call.
What are the three main research categories supported?
The three categories are foundational research and capacity building, applied research and technology development, and early clinical development.
Join the Discussion
What are your thoughts on the expanded funding for T-cell therapies? Share your perspective in the comments below, or subscribe to our newsletter for more updates on scientific research grants.
Related reading